Compare KRNY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KRNY | TECX |
|---|---|---|
| Founded | 1884 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.7M | 549.5M |
| IPO Year | 2014 | N/A |
| Metric | KRNY | TECX |
|---|---|---|
| Price | $9.54 | $32.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $9.25 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 723.6K | 184.8K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 130.22 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $20.75 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $14.39 |
| 52 Week High | $9.76 | $39.53 |
| Indicator | KRNY | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 49.93 |
| Support Level | $9.05 | $27.31 |
| Resistance Level | $9.66 | $35.99 |
| Average True Range (ATR) | 0.21 | 2.74 |
| MACD | -0.02 | -0.46 |
| Stochastic Oscillator | 71.13 | 24.39 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.